Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes

Diabetologia

Volumn 47, Issue 1, 2004, Pages 124-131

  Zhang, S X ^a   Sima, J ^a   Shao, C ^a   Fant, J ^a   Chen, Y ^b   Rohrer, B ^b   Gao, G ^a   Ma, J X ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetic retinopathy; Oxygen induced retinopathy; Permeability; Plasminogen kringle 5; Vascular endothelial growth factor

Indexed keywords

EVANS BLUE; OXYGEN; PLASMINOGEN; RECOMBINANT PLASMINOGEN KRINGLE 5; RECOMBINANT PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOWN REGULATION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HYPEROXIA; IMMUNOHISTOCHEMISTRY; IRIS; MEASUREMENT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; PEPTIDE FRAGMENTS; PLASMINOGEN; RATS; RATS, INBRED BN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0942279561     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1276-4     Document Type: Article

References (38)

1. Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43:134-146
2. Antonetti DA, Lieth E, Barber AJ, Gardner TW (1999) Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 14:240-248
3. Klein R (1996) Diabetic retinopathy. Annu Rev Public Health 17:137-158
4. Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E (1985) Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 34:53-59
5. Yoshida A, Ishiko S, Kojima M, Ogasawara H (1993) Permeability of the blood-ocular barrier in adolescent and adult diabetic patients. Br J Ophthalmol 77:158-161
6. Moss SE, Klein R, Klein BE (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998-1003
7. Qaum T, Xu Q, Joussen AM et al. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413
8. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039
10. Aiello LP, Wong JS (2000) Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77:S113-S119
11. Aiello LP (1997) Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29:354-362
12. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819-825
13. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401-406
14. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M (1997) Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272:22924-22928
15. Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A, Castellino FJ (1998) Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 37:3258-3271
16. Gao G, Li Y, Gee S et al. (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277:9492-9497
17. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX (2001) Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44:757-765
18. Smith LE, Wesolowski E, McLellan A et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111
19. Gao G, Li Y, Fant J, Crosson CE, Beceira SP, Ma JX (2002) Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 51:1218-1225
20. Xu Q, Qaum T, Adamis AP (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789-794
21. Radius RL, Anderson DR (1980) Distribution of albumin in the normal monkey eye as revealed by Evans blue fluorescence microscopy. Invest Ophthalmol Vis Sci 19:238-243
22. Rohrer B, Stell WK (1995) Localization of putative dopamine D2-like receptors in the chick retina, using in situ hybridization and immunocytochemistry. Brain Res 695:110-116
23. Bresnick GH (1986) Diabetic macular edema. A review. Ophthalmology 93:989-997
24. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW (1999) Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 77:170-175
25. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270-276
26. Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117-130
27. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333-346
28. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905-909
29. Senger DR, Connolly DT, Water L van de, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774-1778
30. Adamis AP, Miller JW, Bernal MT et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450
31. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
32. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72:638-645
33. Aiello LP, George DJ, Cahill MT et al. (2002) Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109:1745-1751
34. Ryan AM, Eppler DB, Hagler KE et al. (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78-86
35. Via LE, Gore-Langton RE, Pluda JM (2000) Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Huntington) 14:1321-1323
36. Engerman RL (1976) Animal models of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 81:OP710-OP715
37. Miyamoto K, Khosrof S, Bursell SE et al. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836-10841
38. Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473-1480